Transplant Committee. Long-term clinical monitoring of β-cell functionality in patients with renopancratic transplant or isolated pancreas
DOI:
https://doi.org/10.47196/diab.v58i1Sup.768Keywords:
pancreatic transplant, renopancreas transplant, ß cell functionAbstract
Introduction: renopancreas and isolated pancreas transplantation represent an effective biological treatment for patients with type 1 diabetes and end-stage renal disease. These procedures aim to restore the function of pancreatic ß cells. However, the long-term success of these transplants requires appropriate clinical monitoring to detect potential complications and ensure optimal ß cell function.
Recommendations: for monitoring purposes, we have clinical tools to assess glycemic control and potential biological insults. It is recommended to assess glycemic control using fasting glucose, HbA1c, glucose tolerance tests, and C-peptide. Amylase and lipase serve as markers for subclinical insults against the transplanted pancreas. The interpretation of these tools defines four functional stages: optimal, adequate, marginal, and failure. During follow-up, it is advisable to maintain measures for the prevention and treatment of microvascular and macrovascular complications.
Conclusions: hese monitoring recommendations for renopancreas and isolated pancreas transplant patients are essential for evaluating ß cell functionality and reducing the risk of long-term complications.
References
I. Choudhary P, Rickels MR, Senior PA, Vantyghem M-C, Maffi P, Kay TW, et al. Evidence-informed clinical practice recommendations for treatment of type 1 diabetes complicated by problematic hypoglycemia. Diabetes Care 2015;38:1016-1029.
II. Dean PG, Kukla A, Stegall MD, Kudva YC. Pancreas transplantation. BMJ 2017;357: j1321.
III. Argente-Pla M, Martínez-Millana A, Del Olmo-García MI, Espí-Reig J, Pérez-Rojas J, Traver-Salcedo V, et al. Autoimmune diabetes recurrence after pancreas transplantation: diagnosis, management, and literature review. Ann Transplant 2019;24: 608-616.
IV. Pfeffer F, Nauck MA, Benz S, Gwodzinski A, Zink R, Büsing M, et al. Determinants of a normal (versus impaired) oral glucose tolerance after combined pancreas-kidney transplantation in IDDM patients. Diabetologia 1996;39:462-468.
V. Norman SP, Kommareddi M, Ojo AO, Luan FL. Early pancreas graft failure is associated with inferior late clinical outcomes after simultaneous kidney-pancreas transplantation. Transplantation 2011;92:796-801.
VI. Pugliese A, Reijonen HK, Nepom J, Burke G. Recurrence of autoimmunity in pancreas transplant patients: research update. Diabetes Manag 2011;1:229-238.
VII. Rickels MR, Stock PG, de Koning EJP, Piemonti L, Pratschke J, Alejandro R, et al. Defining outcomes for β-cell replacement therapy in the treatment of diabetes: a consensus report on the Igls criteria from the IPITA/EPITA opinion leaders workshop. Transpl Int 2018;31:343-352.
VIII. Navarro X, Kennedy WR, Aeppli D, Sutherland DE. Neuropathy and mortality in diabetes: influence of pancreas transplantation. Muscle Nerve 1996;19:1009-1016.
IX. Matricali GA, Bammens B, Kuypers D, Flour M, Mathieu C. High rate of Charcot foot attacks early after simultaneous pancreas-kidney transplantation. Transplantation 2007;83:245-246.
X. Wang Q, Klein R, Moss SE, Klein BE, Hoyer C, Burke K, et al. The influence of combined kidney-pancreas transplantation on the progression of diabetic retinopathy. A case series. Ophthalmology 1994;101:1071-1076.
XI. Kim YJ, Shin S, Han DJ, Kim YH, Lee JY, Yoon YH, et al. Long-term effects of pancreas transplantation on diabetic retinopathy and incidence and predictive risk factors for early worsening. Transplantation 2018;102:e30-e38.
XII. Lange UG, Rademacher S, Zirnstein B, Sucher R, Semmling K, Bobbert P, et al. Cardiovascular outcomes after simultaneous pancreas kidney transplantation compared to kidney transplantation alone: a propensity score matching analysis. BMC Nephrol 2021;22: 347.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 on behalf of the authors. Reproduction rights: Argentine Diabetes Society
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
